1[1]Bell DR. Drug treatment of lung cancer. Medical Progress,1998,3(1)∶36-40.
2[2]Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase Ⅰ as an intracellular target of the anticancer drug camptothecin.Cancer Res,1988,48(7)∶1722-1726.
4[5]Lechvalier T, Brigarnd D, Doullard JY, et al. Randomized study of VRB and cisplatin versus vindesize cisplatin versus VRB alone in advanced NSCLC: Result of a Europen multicenter treal including 612 Oucd. J Clin Patients,1994,12(3)∶6007.
4Antoinette JW, Growley JJ, Balcerzak SP, et al. Randomized trail comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A southwest oncology group study. J Clin Oncol, 1998,16:2459.
5Del Tacca M,Di Paolo A,Danesi R.Preclinical pharmacology and clinical uses of topotecan.Tumori,1999,85(6 Suppl 1):S3-S11.
6Hengartner MO.The biochemistry of apoptosis.Nature,2000,407(6805):770-776.
7McCrudden KW,Yokoi A,Thosani A,et al.Topotecan is anti-angiogenic in experimental hepatoblastoma.J Pediatr Surg,2002,37(6):857-861.
8Ferrari D,Stepczynska A,Los M,et al.Differential regulation and ATP requirement for Caspase-8 and Caspase-3 activation during CD95-and anticancer drug-induced apoptosis.J Exp Med,1998,188(5):979-984.
9Mancini M,Nicholson DW,Roy S,et al.The Caspase-3 precursor has a cytosolic and mitochondrial distribution:implications for apoptosis signaling.J Cell Bio1,1998,140(6):1485-1495.
10Westeel V, Bajard A, Jacoulet P, et al. Risk of brain metastases in non-metastic non-small cell lung cancer [J]. Lung Cancer, 2003, 41(Suppl 2) : S21.
